Evaluation of antileishmanial and antibacterial activity of bioconjugate guanidine-temporin.
SANTORO, Gabriel Antunes; COSTA, Natália Caroline Silva; BRANDÃO, Sarah Tolentino Rocha; LIMA, Jhonatan Santos de; VELÁSQUEZ, Angela Maria Arenas; ANJOS, Luana Ribeiro dos; ABRÃO, Cauã Dias; SOUZA, João Victor Marcelino de; ARGENTIN, Marcela Nunes; CAMARGO, Ilana Lopes Baratella da Cunha; GRAMINHA, Marcia Aparecida Silva; GONZALEZ, Eduardo Rene Perez; CILLI, Eduardo Maffud.
SANTORO, Gabriel Antunes; COSTA, Natália Caroline Silva; BRANDÃO, Sarah Tolentino Rocha; LIMA, Jhonatan Santos de; VELÁSQUEZ, Angela Maria Arenas; ANJOS, Luana Ribeiro dos; ABRÃO, Cauã Dias; SOUZA, João Victor Marcelino de; ARGENTIN, Marcela Nunes; CAMARGO, Ilana Lopes Baratella da Cunha; GRAMINHA, Marcia Aparecida Silva; GONZALEZ, Eduardo Rene Perez; CILLI, Eduardo Maffud.
Abstract: Background: Peptides are promising tools in medicine for viral, bacterial, and parasitic infections. MAP1 and MAP2 are peptides with antimicrobial activity. Aiming to increase selectivity, enhance antimicrobial activity, and reduce its cytotoxicity, two bioconjugates (GVL1-MAP2 and GVL1-MAP1) with the guanidine derivative group in the N-terminus position were synthesized. Methods: The peptides and bioconjugates were synthesized by SPPS. The biological activity and inhibition of the CPB enzyme were evaluated. Results: Antileishmanial activity was evaluated, and the bioconjugates exhibited higher activity in both the promastigote and amastigote forms than isolated GVL1 and peptides alone. Discussion: GVL1-MAP2 bioconjugate demonstrated not only the greatest activity against L. amazonensis in the promastigote (IC50 = 3.2 µM) and amastigote (IC50 = 0.6 µM) forms but also prevented the parasite from infecting new host cells, reducing the infection rate by 3-fold compared to the untreated control. Similar results were obtained in L. infantum, with IC50 = 2.5 and 1.0 µM for promastigote and amastigote forms, respectively. In active serum, GVL1-MAP2 continued to show high activity. GVL1-MAP2 also showed bactericidal activity against most strains tested. The bioconjugate GVL1-MAP2 showed lower cytotoxicity than GVL1-MAP1 and amphotericin B in macrophages. Permeabilization studies and enzyme inhibition revealed that the peptide acts via at least two distinct mechanisms, with the primary mechanism targeting the membrane and inner targets as an inhibitor of the CPB enzyme. Conclusions: These data demonstrated that the synthesis of bioconjugates can be a tool for the development of bactericidal and antileishmanial compounds with improved potency and selectivity.
@article={003306036,author = {SANTORO, Gabriel Antunes; COSTA, Natália Caroline Silva; BRANDÃO, Sarah Tolentino Rocha; LIMA, Jhonatan Santos de; VELÁSQUEZ, Angela Maria Arenas; ANJOS, Luana Ribeiro dos; ABRÃO, Cauã Dias; SOUZA, João Victor Marcelino de; ARGENTIN, Marcela Nunes; CAMARGO, Ilana Lopes Baratella da Cunha; GRAMINHA, Marcia Aparecida Silva; GONZALEZ, Eduardo Rene Perez; CILLI, Eduardo Maffud.},title={Evaluation of antileishmanial and antibacterial activity of bioconjugate guanidine-temporin},journal={Pharmaceuticals},note={v. 19, n. 6, p. 835-1-835-21 + supplementary materials},year={2026}}